Chemed Corporation $CHE Shares Sold by Signal Advisors Wealth LLC

Signal Advisors Wealth LLC reduced its holdings in shares of Chemed Corporation (NYSE:CHE) by 13.9% in the third quarter, Holdings Channel.com reports. The fund owned 17,713 shares of the company’s stock after selling 2,852 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Chemed were worth $8,946,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of CHE. Quantbot Technologies LP purchased a new stake in Chemed in the second quarter worth $1,726,000. The Manufacturers Life Insurance Company bought a new stake in shares of Chemed during the second quarter worth $4,413,000. Lone Peak Global Investors LLC boosted its stake in shares of Chemed by 38.1% during the second quarter. Lone Peak Global Investors LLC now owns 37,099 shares of the company’s stock valued at $17,279,000 after purchasing an additional 10,226 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Chemed by 41.7% during the second quarter. Hsbc Holdings PLC now owns 12,346 shares of the company’s stock valued at $5,729,000 after purchasing an additional 3,632 shares during the period. Finally, Amundi grew its holdings in shares of Chemed by 51.5% in the second quarter. Amundi now owns 53,856 shares of the company’s stock worth $25,083,000 after purchasing an additional 18,301 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Insider Activity

In related news, EVP Spencer Lee sold 1,000 shares of Chemed stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $541.04, for a total value of $541,040.00. Following the completion of the sale, the executive vice president directly owned 13,912 shares in the company, valued at $7,526,948.48. The trade was a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin McNamara sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the sale, the chief executive officer directly owned 70,418 shares of the company’s stock, valued at approximately $37,991,215.18. This trade represents a 2.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 9,190 shares of company stock worth $4,833,160. Company insiders own 3.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Oppenheimer raised their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Royal Bank Of Canada lifted their price objective on shares of Chemed from $436.00 to $548.00 and gave the company a “sector perform” rating in a report on Thursday, July 30th. Wall Street Zen raised shares of Chemed from a “buy” rating to a “strong-buy” rating in a research report on Saturday. UBS Group began coverage on shares of Chemed in a research note on Friday, September 25th. They issued a “buy” rating and a $650.00 target price on the stock. Finally, Bank of America restated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $554.60.

Chemed Stock Up 0.1%

Shares of NYSE:CHE opened at $501.18 on Wednesday. The business’s 50 day moving average is $519.71 and its 200 day moving average is $468.79. The stock has a market cap of $6.55 billion, a P/E ratio of 25.17, a price-to-earnings-growth ratio of 2.01 and a beta of 0.51. Chemed Corporation has a 52-week low of $365.20 and a 52-week high of $557.00. The company has a quick ratio of 0.89, a current ratio of 0.91 and a debt-to-equity ratio of 0.17.

Chemed (NYSE:CHE) last issued its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%. The business had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. During the same period in the previous year, the company posted $4.27 EPS. Chemed’s revenue was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Sell-side analysts predict that Chemed Corporation will post 23.55 EPS for the current year.

Chemed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were paid a dividend of $0.70 per share. This is an increase from Chemed’s previous quarterly dividend of $0.60. This represents a $2.80 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 17th. Chemed’s payout ratio is 14.06%.

About Chemed

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.